
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Endocrine</journal-id><journal-id journal-id-type="iso-abbrev">Endocrine</journal-id><journal-title-group><journal-title>Endocrine</journal-title></journal-title-group><issn pub-type="ppub">1355-008X</issn><issn pub-type="epub">1559-0100</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27553050</article-id><article-id pub-id-type="pmc">5566489</article-id><article-id pub-id-type="publisher-id">1074</article-id><article-id pub-id-type="doi">10.1007/s12020-016-1074-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Calculation of therapeutic activity of radioiodine in
Graves&#x02019; disease by means of Marinelli&#x02019;s formula, using technetium
(<sup>99m</sup>Tc) scintigraphy</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Szumowski</surname><given-names>Piotr</given-names></name><address><phone>+48 85 746 87 70</phone><email>piotrmjs@wp.pl</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Mojsak</surname><given-names>Ma&#x00142;gorzata</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Abdelrazek</surname><given-names>Saeid</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Syka&#x00142;a</surname><given-names>Monika</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Amelian-Fi&#x00142;onowicz</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Jurgilewicz</surname><given-names>Dorota</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>My&#x0015b;liwiec</surname><given-names>Janusz</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Department of Nuclear Medicine, Medical University of Bialystok, M. Sk&#x00142;odowskiej-Curie St. 24A, 15&#x02013;276 Bialystok, Poland </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>8</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>8</month><year>2016</year></pub-date><pub-date pub-type="ppub"><year>2016</year></pub-date><volume>54</volume><issue>3</issue><fpage>751</fpage><lpage>756</lpage><history><date date-type="received"><day>30</day><month>3</month><year>2016</year></date><date date-type="accepted"><day>29</day><month>6</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2016</copyright-statement><license license-type="OpenAccess"><license-p>This article is distributed under the terms of the Creative Commons
Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in
any medium, provided you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if changes
were made.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">The therapeutic activity of <sup>131</sup>I
administered to patients with Graves&#x02019; disease can be calculated by means of
Marinelli&#x02019;s formula. The thyroidal iodine uptake
(<sup>131</sup>IU<sub>max</sub>) needed for the
calculation is usually determined with the use of <sup>131</sup>I.
The purpose of the paper was to estimate
<sup>131</sup>IU<sub>max</sub> on the basis of
technetium uptake in the thyroid at 20&#x02009;min
(<sup>99m</sup>TcU<sub>20min</sub>). Eighty patients
suffering from Graves&#x02019; disease were qualified for radioiodine therapy with
measurement of fT<sub>4</sub>, fT<sub>3</sub>,
thyroid-stimulating hormone and its receptor (TRAb). Prior to the treatment, all the
patients were euthyroid. <sup>131</sup>IU<sub>max</sub>
for each patient was determined according to the levels of
<sup>131</sup>I after 24&#x02009;h
(<sup>131</sup>IU<sub>24h</sub>), while effective
half-life (<italic>T</italic>
<sub>eff</sub>) according to the measurements of
<sup>131</sup>IU<sub>24h</sub> and
<sup>131</sup>I uptake after 48&#x02009;h
(<sup>131</sup>IU<sub>48h</sub>). Additionally, on the
day before measuring <sup>131</sup>IU<sub>24h</sub>,
<sup>99m</sup>TcU<sub>20min</sub> was calculated for
each patient. It was demonstrated that there existed a correlation, with statistical
significance at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, between the
following pairs of values: TRAb and
<sup>131</sup>IU<sub>24h</sub>, TRAb and
<sup>99m</sup>TcU<sub>20min</sub>, and
<sup>99m</sup>TcU<sub>20min</sub> and
<sup>131</sup>IU<sub>24h</sub>. The interdependence
between <sup>131</sup>IU<sub>24h</sub> and
<sup>99m</sup>TcU<sub>20min</sub> at the level of
significance <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 is described by the
following algorithms:
<sup>131</sup>IU<sub>24h</sub>&#x02009;=&#x02009;17.72&#x02009;&#x000d7;&#x02009;ln
(<sup>99m</sup>TcU<sub>20min</sub>)&#x02009;+&#x02009;30.485, if
TRAb&#x02009;&#x0003c;&#x02009;10&#x02009;IU/ml, and
<sup>131</sup>IU<sub>24h</sub>&#x02009;=&#x02009;18.03&#x02009;&#x000d7;&#x02009;ln
(<sup>99m</sup>TcU<sub>20min</sub>)&#x02009;+&#x02009;38.726, if
TRAb&#x02009;&#x0003e;&#x02009;10&#x02009;IU/ml. It is possible to predict thyroid iodine uptake
<sup>131</sup>IU<sub>24h</sub> in Graves&#x02019; disease on
the basis of measuring the uptake of
<sup>99m</sup>TcU<sub>20min</sub>. This shortens the
time necessary for diagnosis and enables the calculation of
<sup>131</sup>I activity using Marinelli&#x02019;s formula.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Marinelli&#x02019;s formula</kwd><kwd>Thyroid iodine uptake</kwd><kwd>Thyroid technetium uptake</kwd><kwd>Graves&#x02019; disease</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media New York 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Radiotherapy is, apart from pharmacotherapy and surgical intervention,
one of the major methods of treatment for Graves&#x02019; disease (GD). Effective
radioiodine therapy for GD consists in calculating an appropriate activity of the
radioisotope in order to achieve the highest possible therapeutic efficacy, with the
lowest possible radiation of the thyroid, and thus of the patient. The clinics that
offer radioiodine therapy in Europe and around the world use various methods of
selecting correct therapeutic activities of <sup>131</sup>I. Our
department applies the Marinelli formula, which is recommended by the European
Association of Nuclear Medicine (EANM) [<xref ref-type="bibr" rid="CR1">1</xref>]. Radioiodine <sup>131</sup>I is usually used to
determine the thyroidal iodine uptake required by the formula. Some also use the
iodine isotope <sup>123</sup>I, although much less frequently
because of the high costs of its production in a cyclotron [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>].
The disadvantages of using <sup>131</sup>I for therapeutic purposes
include: beta radiation during radioactive decay, relatively high gamma radiation
energy (364&#x02009;keV) and the long time (usually 24&#x02009;h) that is required for assessing the
maximum iodine uptake in the thyroid. Technetium <sup>99m</sup>Tc is
another isotope which, like <sup>131</sup>I, is absorbed by
thyrocytes, thanks to sodium/iodide symporter (NIS) proteins. Contrary to
<sup>131</sup>I, it is a pure emitter of gamma radiation, with a
much shorter half-life (<italic>T</italic>
<sub>1/2</sub>) of 6.04&#x02009;h (8 days in the case of
<sup>131</sup>I). Moreover, the gamma radiation of technetium
carries far less energy than that of iodine (140&#x02009;keV). Also the time needed for the
assessment of its maximum uptake by the thyroid is much shorter than in the case of
<sup>131</sup>I and equals only 20&#x02009;min. This allows to diminish
the time of thyroid diagnostic. As far as their metabolism in thyroid cells is
concerned, a major difference between <sup>99m</sup>Tc and
<sup>131</sup>I is that the former does not participate in the
synthesis of hormones. Nevertheless, the thyroidal uptake of both
<sup>9m</sup>Tc and <sup>131</sup>I in GD depends
primarily on the level of thyroid-stimulating hormone (TSH) receptor antibodies
(TRAbs), which stimulate the NIS protein to active transport of isotopes into
thyrocytes, as well as by intercellular metabolism [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. The question
arises, therefore, whether the assessment of thyroid iodine uptake needed for
Marinelli&#x02019;s formula could be performed with the help of
<sup>99m</sup>Tc. Thus the aims of this study were as follows:<list list-type="order"><list-item><p id="Par3">An attempt to create an algorithm to assess thyroidal iodine
uptake in GD patients qualified for radioactive iodine therapy on the basis
of <sup>99m</sup>Tc scintigraphy of the thyroid.</p></list-item><list-item><p id="Par4">Transformation of Marinelli&#x02019;s formula used for calculating
therapeutic activities of <sup>131</sup>I by substituting
thyroid iodine uptake with thyroid <sup>99m</sup>Tc
uptake.</p></list-item></list>
</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><p id="Par5">The study sample comprised 80 GD patients: 61 women and 19 men. All
the subjects had been referred to the Department of Nuclear Medicine with a view to
treating hyperthyroidism, following unsuccessful attempts at pharmacotherapy with
thyrostatic drugs (the treatment periods being no shorter than 1.5 years). Prior to
the administration of a therapeutic dose of <sup>131</sup>I, each
patient had undergone routine eligibility screening, involving an initial
measurement of the thyrotropic hormone, TSH (reference range 0.3&#x02013;4.0&#x02009;&#x000b5;IU/ml), free
thyroxine, fT<sub>4</sub> (reference range 0.71&#x02013;1.85&#x02009;ng/dl) and free
triiodothyronine, fT<sub>3</sub> (reference range 1.45&#x02013;3.48&#x02009;pg/mL),
using the immunoenzymatic method, Microparticle Enzyme Immunoassay (Abbott Park,
USA), and TSH-TRAb (normal&#x02009;&#x0003c;&#x02009;2&#x02009;IU/l) using the radioimmunological method (TRAK
Human BRAHMS, Germany). Subsequently it was decided that further diagnostics could
only involve those subjects who were euthyroid. Hyperthyroid patients continued to
be treated with thyrostatics until euthyroid, up to 2 days before the study.</p><p id="Par6">Next, the 24- and 48-h thyroidal iodine uptake tests were carried out
after per os (fasting) administration of a capsule containing
<sup>131</sup>I with the activity of 4&#x02009;MBq. Additionally, 1 day
before the IU<sub>24h</sub>, scintigrams of the thyroid glands were
performed, following an intravenous administration of 80&#x02009;MBq
<sup>99m</sup>Tc. The readouts of thyroid-absorbed radiation began
at 20&#x02009;min of the administration of the radio marker. Both the iodine uptake tests
and the technetium scintigraphy estimating the marker&#x02019;s uptake in the gland were
performed with a gamma-camera (NuclineTM Th, Mediso, Hungary), in accordance with
the standard procedures. The volume of the thyroid (<italic>m</italic>) was estimated by means of a ultrasonography (USG). USG device was
equipped with a 12&#x02009;L linear transducer (LOGIQ S8, GE Healthcare, USA).</p><p id="Par7">The required therapeutic activity of <sup>131</sup>I
(<italic>A</italic>) was calculated with Marinelli&#x02019;s formula
[<xref ref-type="bibr" rid="CR6">6</xref>]:<disp-formula id="Equ1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$A = \frac{{25 \cdot m \cdot D}}{{I{U_{24h}} \cdot {T_{eff}}}}$$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mi>A</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>25</mml:mn><mml:mo>&#x022c5;</mml:mo><mml:mi>m</mml:mi><mml:mo>&#x022c5;</mml:mo><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:msub><mml:mrow><mml:mi>U</mml:mi></mml:mrow><mml:mrow><mml:mn>24</mml:mn><mml:mi>h</mml:mi></mml:mrow></mml:msub><mml:mo>&#x022c5;</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math><graphic xlink:href="12020_2016_1074_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula>where</p><p id="Par8">A&#x02014;<sup><italic>131</italic></sup>
<italic>I therapeutic activity (MBq)</italic>
</p><p id="Par9">25&#x02014;<italic>unit conversion coefficient</italic>
</p><p id="Par10">
<italic>m</italic>&#x02014;<italic>mass of thyroid gland
calculated with USG (g)</italic>
</p><p id="Par11">D&#x02014;<italic>absorbed dose of</italic>
<sup><italic>131</italic></sup>
<italic>I (Gy), with D</italic>&#x02009;=&#x02009;<italic>150&#x02009;Gy,
as recommended by EANM for GD</italic> [<xref ref-type="bibr" rid="CR1">1</xref>]</p><p id="Par12">
<italic>IU</italic>
<sub><italic>24h</italic></sub>&#x02014;<italic>24-h</italic>
<sup><italic>131</italic></sup>
<italic>I uptake (%)</italic>
</p><p id="Par13">
<italic>T</italic>
<sub>eff</sub>&#x02014;<italic>effective</italic>
<sup><italic>131</italic></sup>
<italic>I half-life in thyroid gland (days) calculated with
gamma-camera based on</italic>
<sup><italic>131</italic></sup>
<italic>IU</italic>
<sub><italic>24h</italic></sub>
<italic>and</italic>
<sup><italic>131</italic></sup>
<italic>IU</italic>
<sub><italic>48h</italic></sub>
</p><p id="Par14">The study was approved by the Ethics Committee for Medical Research,
Medical University, and is compliant with the good clinical practice guidelines.
Informed consent was given by all patients participating in the study.</p><sec id="Sec3"><title>Statistical analysis</title><p id="Par15">The statistical analysis of the results of the study was conducted
using the software package Statistica 10 (Stat Soft, Tulsa, USA).</p><p id="Par16">A multivariate analysis of variance was used to investigate the
influence of fT<sub>4</sub>, fT<sub>3</sub>, TSH,
<italic>m</italic> and TRAb on IU<sub>24h</sub>,
<italic>T</italic>
<sub>eff</sub> and
<sup>99m</sup>TcU<sub>20min</sub>. The significance
level was <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p><p id="Par17">The non-linear regression function was used to establish the
correlation of the IU<sub>24h</sub>,
<sup>99m</sup>TcU<sub>20min</sub> and TRAb
parameters, with the level of significance at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></sec></sec><sec id="Sec4" sec-type="results"><title>Results</title><p id="Par18">It can be noticed among the parameters measured in GD patients in the
course of the eligibility study, the effective <sup>131</sup>I
half-life in the thyroid gland (<italic>T</italic>
<sub>eff</sub>) has a very low standard deviation (&#x000b1;0.04) and that its
mean value equals 5.5 days, while the serum level of thyroid hormones in all the
patients before treatment remains within the normal limits, thanks to an effective
therapy with thyrostatic medications (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Parameters measured during eligibility screening of GD patients to
be treated with <sup>131</sup>I</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>TSH (&#x000b5;IU/ml)</th><th>fT<sub>3</sub> (pg/ml)</th><th>fT<sub>4</sub> (ng/dl)</th><th>TRAb (IU/l)</th><th>
<italic>m</italic> (g)</th><th>
<sup>99m</sup>TcU<sub>20min</sub>
(%)</th><th>IU<sub>24h</sub> (%)</th><th>
<italic>T</italic>
<sub>eff</sub> (days)</th></tr></thead><tbody><tr><td>Mean</td><td char="." align="char">1.34</td><td char="." align="char">2.54</td><td char="." align="char">1.21</td><td char="." align="char">10.9</td><td char="." align="char">31.6</td><td char="." align="char">2.3</td><td char="." align="char">45</td><td char="." align="char">5.5</td></tr><tr><td>Standard deviation</td><td char="." align="char">&#x000b1;0.19</td><td char="." align="char">&#x000b1;0.36</td><td char="." align="char">&#x000b1;0.4</td><td char="." align="char">&#x000b1;14.8</td><td char="." align="char">&#x000b1;18.6</td><td char="." align="char">&#x000b1;3.4</td><td char="." align="char">&#x000b1;15.8</td><td char="." align="char">&#x000b1;0.04</td></tr><tr><td>Maximum</td><td char="." align="char">4.67</td><td char="." align="char">3.31</td><td char="." align="char">1.41</td><td char="." align="char">39.7</td><td char="." align="char">64.3</td><td char="." align="char">8.1</td><td char="." align="char">68</td><td char="." align="char">5.9</td></tr><tr><td>Minimum</td><td char="." align="char">0.54</td><td char="." align="char">1.54</td><td char="." align="char">1.01</td><td char="." align="char">1.7</td><td char="." align="char">19.4</td><td char="." align="char">1.1</td><td char="." align="char">32</td><td char="." align="char">5.17</td></tr></tbody></table><table-wrap-foot><p>
<italic>fT</italic>
<sub><italic>4</italic></sub> free thyroxine, <italic>fT</italic>
<sub><italic>3</italic></sub> free triiodothyronine, <italic>m</italic> mass
of thyroid, <sup><italic>99m</italic></sup>
<italic>TcU</italic>
<sub><italic>20min</italic></sub> 20-min <sup>99m</sup>Tc uptake, <italic>IU</italic>
<sub><italic>24h</italic></sub> 24-h <sup>131</sup>I uptake, <italic>T</italic>
<sub>eff</sub> effective <sup>131</sup>I half-life
in thyroid gland, <italic>TRAb</italic> antibodies against
TSH receptor, <italic>TSH</italic> thyroid-stimulating
hormone</p></table-wrap-foot></table-wrap>
</p><p id="Par19">Comparison of the parameters measured in the patients during the
eligibility screening period demonstrates that there exists a statistically
significant (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) correlation between the
following pairs: TRAb and
<sup>131</sup>IU<sub>24h</sub>, TRAb and
<sup>99m</sup>TcU<sub>20min</sub>,
<sup>99m</sup>TcU<sub>20min</sub> and
<sup>131</sup>IU<sub>24h</sub> (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Coefficients of correlation between parameters</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>TSH (&#x000b5;IU/ml)</th><th>fT<sub>4</sub> (ng/dl)</th><th>fT<sub>3</sub> (pg/ml)</th><th>
<italic>m</italic> (g)</th><th>TRAb (IU/l)</th><th>
<sup>99m</sup>TcU<sub>20min</sub>
(%)</th><th>
<sup>131</sup>IU<sub>24h</sub>
(%)</th><th>
<italic>T</italic>
<sub>eff</sub> (days)</th></tr></thead><tbody><tr><td colspan="9">TSH (&#x000b5;IU/ml)</td></tr><tr><td>fT<sub>4</sub> (ng/dl)</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.56</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td/><td>(<italic>p</italic>&#x02009;=&#x02009;0.072)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>fT<sub>3</sub> (pg/ml)</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.43</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.59</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td>(<italic>p</italic>&#x02009;=&#x02009;0.091)</td><td>(<italic>p</italic>&#x02009;=&#x02009;0.301)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>
<italic>m</italic> (g)</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.24</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.31</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.28</td><td/><td/><td/><td/><td/></tr><tr><td/><td>(<italic>p</italic>&#x02009;=&#x02009;0.086)</td><td>(<italic>p</italic>&#x02009;=&#x02009;0.201)</td><td>(<italic>p</italic>&#x02009;=&#x02009;0.501)</td><td/><td/><td/><td/><td/></tr><tr><td>TRAb (IU/l)</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.2</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.43</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.35</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.23</td><td/><td/><td/><td/></tr><tr><td/><td>(<italic>p</italic>&#x02009;=&#x02009;0.123)</td><td>(<italic>p</italic>&#x02009;=&#x02009;0.078)</td><td>(<italic>p</italic>&#x02009;=&#x02009;0.101)</td><td>(<italic>p</italic>&#x02009;=&#x02009;0.134)</td><td/><td/><td/><td/></tr><tr><td>
<sup>99m</sup>TcU<sub>20min</sub>
(%)</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.34</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.56</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.66</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.37</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.70<sup>a</sup>
</td><td/><td/><td/></tr><tr><td/><td>(<italic>p</italic>&#x02009;=&#x02009;0.061)</td><td>(<italic>p</italic>&#x02009;=&#x02009;0.058)</td><td>(<italic>p</italic>&#x02009;=&#x02009;0.069)</td><td>(<italic>p</italic>&#x02009;=&#x02009;0.068)</td><td>(<italic>p</italic>&#x02009;=&#x02009;0.013)</td><td/><td/><td/></tr><tr><td>
<sup>131</sup>IU<sub>24h</sub>
(%)</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.57</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.54</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.51</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.32</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.73<sup>b</sup>
</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.89<sup>c</sup>
</td><td/><td/></tr><tr><td/><td>(<italic>p</italic>&#x02009;=&#x02009;0.056)</td><td>(<italic>p</italic>&#x02009;=&#x02009;0.059)</td><td>(<italic>p</italic>&#x02009;=&#x02009;0.059)</td><td>(<italic>p</italic>&#x02009;=&#x02009;0.081)</td><td>(<italic>p</italic>&#x02009;=&#x02009;0.021)</td><td>(<italic>p</italic>&#x02009;=&#x02009;0.031)</td><td/><td/></tr><tr><td>
<italic>T</italic>
<sub>eff</sub> (days)</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.47</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.61</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.46</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.198</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.28</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.31</td><td>
<italic>r</italic>&#x02009;=&#x02009;0.5</td><td/></tr><tr><td/><td>(<italic>p</italic>&#x02009;=&#x02009;0.057)</td><td>(<italic>p</italic>&#x02009;=&#x02009;0.061)</td><td>(<italic>p</italic>&#x02009;=&#x02009;0.072)</td><td>(<italic>p</italic>&#x02009;=&#x02009;0.203)</td><td>(<italic>p</italic>&#x02009;=&#x02009;0.078)</td><td>(<italic>p</italic>&#x02009;=&#x02009;0.099)</td><td>(<italic>p</italic>&#x02009;=&#x02009;0.105)</td><td/></tr></tbody></table><table-wrap-foot><p>Abbreviations: see Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>
</p><p>
<sup>a,b,c</sup> Correlation coefficients occurring with
statistical significance of <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05</p><p>The other correlation coefficients in the table do not meet the
<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 condition</p></table-wrap-foot></table-wrap>
</p><p id="Par20">The statistical analysis revealed that the highest correlation
between <sup>99m</sup>Tc and <sup>131</sup>I occurs
when the TRAb titre is either &#x0003c;10&#x02009;IU/ml or &#x0003e;10&#x02009;IU/ml.</p><p id="Par21">Using this information, further analysis involved the non-linear
regression model in order to generate a mathematical formula that would describe the
relationship between <sup>131</sup>IU<sub>24h</sub> and
<sup>99m</sup>TcU<sub>20min</sub> for the two ranges
of TRAb titres, assuming the significance at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05. It stems from the calculations (Figs.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> and&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>) that
the regression model that predicts the dependence of IU<sub>24h</sub> on
<sup>99m</sup>TcU<sub>20min</sub>, if
TRAb&#x02009;&#x0003c;&#x02009;10&#x02009;IU/ml, looks as follows:<disp-formula id="Equ2"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{131}{\rm IU}_{{\rm 24h}} = 17.72 \times {\rm ln}({99\rm m} {\rm TcU}_{\rm 20min}) + 30.485$$\end{document}</tex-math><mml:math id="M4" display="block"><mml:msup><mml:mrow/><mml:mrow><mml:mn>131</mml:mn></mml:mrow></mml:msup><mml:msub><mml:mrow><mml:mi>I</mml:mi><mml:mi>U</mml:mi></mml:mrow><mml:mrow><mml:mn>24</mml:mn><mml:mi>h</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>17</mml:mn><mml:mo>.</mml:mo><mml:mn>72</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>99</mml:mn><mml:mi>m</mml:mi><mml:msub><mml:mrow><mml:mi>T</mml:mi><mml:mi>c</mml:mi><mml:mi>U</mml:mi></mml:mrow><mml:mrow><mml:mn>20</mml:mn><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mn>30</mml:mn><mml:mo>.</mml:mo><mml:mn>485</mml:mn></mml:math><graphic xlink:href="12020_2016_1074_Article_Equ2.gif" position="anchor"/></alternatives></disp-formula>whereas if TRAb&#x02009;&#x0003e;&#x02009;10&#x02009;IU/ml:<disp-formula id="Equ3"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{131}{\rm IU}_{\rm 24h} = 18.03 \times {\rm ln}({\rm 99m}{\rm TcU}_{\rm 20min}) + 38.726$$\end{document}</tex-math><mml:math id="M6" display="block"><mml:msup><mml:mrow/><mml:mrow><mml:mn>131</mml:mn></mml:mrow></mml:msup><mml:msub><mml:mrow><mml:mi>I</mml:mi><mml:mi>U</mml:mi></mml:mrow><mml:mrow><mml:mn>24</mml:mn><mml:mi>h</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>18</mml:mn><mml:mo>.</mml:mo><mml:mn>03</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>99</mml:mn><mml:mi>m</mml:mi><mml:msub><mml:mrow><mml:mi>T</mml:mi><mml:mi>c</mml:mi><mml:mi>U</mml:mi></mml:mrow><mml:mrow><mml:mn>20</mml:mn><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mn>38</mml:mn><mml:mo>.</mml:mo><mml:mn>726</mml:mn></mml:math><graphic xlink:href="12020_2016_1074_Article_Equ3.gif" position="anchor"/></alternatives></disp-formula>
<fig id="Fig1"><label>Fig. 1</label><caption><p>Scatter graph for variables
<sup>99m</sup>TcU<sub>20min</sub> and
<sup>131</sup>IU<sub>24h</sub>, with
TRAb&#x02009;&#x0003c;&#x02009;10&#x02009;IU/ml, and regression equation illustrating their
relationship</p></caption><graphic xlink:href="12020_2016_1074_Fig1_HTML" id="d29e1827"/></fig>
<fig id="Fig2"><label>Fig. 2</label><caption><p>Scatter graph for variables
<sup>99m</sup>TcU<sub>20min</sub> and
<sup>131</sup>IU<sub>24h</sub>, with
TRAb&#x02009;&#x0003e;&#x02009;10&#x02009;IU/ml, and regression equation illustrating their
relationship</p></caption><graphic xlink:href="12020_2016_1074_Fig2_HTML" id="d29e1849"/></fig>
</p><p id="Par22">By substituting
<sup>131</sup>IU<sub>24h</sub> in the Marinelli
formula with the above correlations, and <italic>T</italic>
<sub>eff</sub> with the number 5.5 (the value of <italic>T</italic>
<sub>eff</sub> in all the patients equalled approximately 5.5; see
Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>), we will obtain transformed
formulas that can be used to calculate the therapeutic activity of
<sup>131</sup>I on the basis of thyroid
<sup>99m</sup>TcU<sub>20min</sub> uptake.</p><p id="Par23">If TRAb&#x02009;&#x0003c;&#x02009;10&#x02009;IU/ml, the transformed Marinelli&#x02019;s formula takes this
form:<disp-formula id="Equ4"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$A\left( {\rm{MBq}} \right) = \frac{{25 \times m({\rm{g}}) \times D({\rm{G}})}}{{17.72 \times [{\rm{ln}}({}{{\rm{99m}}}{\rm{Tc}}{{\rm{U}}_{{\rm{20min}}}}) + 30.485] \times 5.5}}$$\end{document}</tex-math><mml:math id="M8" display="block"><mml:mi>A</mml:mi><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:mi>M</mml:mi><mml:mi>B</mml:mi><mml:mi>q</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>25</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>g</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:mi>D</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mn>17</mml:mn><mml:mo>.</mml:mo><mml:mn>72</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>99</mml:mn><mml:mi>m</mml:mi><mml:mi>T</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mrow><mml:mi>U</mml:mi></mml:mrow><mml:mrow><mml:mn>20</mml:mn><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mn>30</mml:mn><mml:mo>.</mml:mo><mml:mn>485</mml:mn></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:mn>5</mml:mn><mml:mo>.</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:mfrac></mml:math><graphic xlink:href="12020_2016_1074_Article_Equ4.gif" position="anchor"/></alternatives></disp-formula>whereas if TRAb&#x02009;&#x0003e;&#x02009;10&#x02009;IU/ml, it looks as follows:<disp-formula id="Equ5"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$A({\rm{MBq}}) = \frac{{25 \times m({\rm{g}}) \times D({\rm{G}})}}{{18.03 \times [{\rm{ln}}({}{{\rm{99m}}}{\rm{Tc}}{{\rm{U}}_{{\rm{20min}}}}) + 38.726] \times 5.5}}$$\end{document}</tex-math><mml:math id="M10" display="block"><mml:mi>A</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>M</mml:mi><mml:mi>B</mml:mi><mml:mi>q</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>25</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>g</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:mi>D</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mn>18</mml:mn><mml:mo>.</mml:mo><mml:mn>03</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>99</mml:mn><mml:mi>m</mml:mi><mml:mi>T</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mrow><mml:mi>U</mml:mi></mml:mrow><mml:mrow><mml:mn>20</mml:mn><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mn>38</mml:mn><mml:mo>.</mml:mo><mml:mn>726</mml:mn></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:mn>5</mml:mn><mml:mo>.</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:mfrac></mml:math><graphic xlink:href="12020_2016_1074_Article_Equ5.gif" position="anchor"/></alternatives></disp-formula>
</p></sec><sec id="Sec5" sec-type="discussion"><title>Discussion</title><p id="Par24">The therapeutic effect of the ionising radiation of
<sup>131</sup>I applied in the course of hyperthyroidism treatment
depends above all on the dose of radiation absorbed by the thyroid gland. This
statement is one of the key points of the standards regarding radioiodine treatment
for hyperthyroidism issued by the EANM. The EANM guidelines mention the ranges of
absorbed doses of ionising radiation according to the type of hyperthyroidism. In
patients with autonomous nodules, the recommended dose is 300&#x02013;400&#x02009;Gy. In patients
with GD, the dose with the aim of restoring a euthyroid status is approximately
150&#x02009;Gy, whereas the dose to achieve complete ablation is in the range 200&#x02013;300&#x02009;Gy.
For calculating the therapeutic activity of radioiodine, the EANM guidelines
recommend the Marinelli formula. Apart from the aforementioned absorbed dose, the
formula requires the evaluation of maximum thyroidal iodine uptake and of the
effective half-life of radioiodine in the thyroid [<xref ref-type="bibr" rid="CR1">1</xref>]. In an accurately prepared GD patient, the effective half-life
has&#x02014;according to our calculations&#x02014;a steady value of 5.5 days on average
[<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>]. This is why we are convinced that Marinelli&#x02019;s formula can be
simplified by substituting <italic>T</italic>
<sub>eff</sub> with 5.5 days.</p><p id="Par25">In their attempts to streamline the calculation of the therapeutic
activity of radioactive iodine using Marinelli&#x02019;s formula, some authors resort to a
variety of methods to determine the value of maximum thyroid iodine uptake. As a
rule, the maximum uptake occurs after 24&#x02009;h of the administration of radioactive
iodine (<sup>131</sup>I) [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. Morris and
Hayes et al. propose algorithms for predicting <sup>131</sup>I
uptake through measuring it after 4 or 6&#x02009;h, which considerably shortens the time of
the procedure. In Morris&#x02019; study, the difference between the actual 24&#x02009;h measurement
and the estimated value after 4&#x02009;h amounted to +10&#x02009;%, and +5.9&#x02009;% after 6&#x02009;h. Hayes et
al., meanwhile, proved that the correlation coefficient between the actual
measurements and the 4- and 6-h estimates was high, reaching <italic>r</italic>&#x02009;=&#x02009;0.94 [<xref ref-type="bibr" rid="CR13">13</xref>,
<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par26">Still another approach to the problem can be found in the research
results published by authors such as Shapiro or Yaqub. In both studies the maximum
thyroid uptake in GD patients was calculated&#x02014;as it usually is&#x02014;after 24&#x02009;h, but it was
done by means of <sup>123</sup>I instead of
<sup>131</sup>I. <sup>123</sup>I possesses better
physical parameters for isotope diagnostics (<sup>123</sup>I, in
contrast to <sup>131</sup>I, is a pure emitter of gamma radiation,
characterised by a lower energy level and shorter half-life) [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Osaki et al. combined the above two approaches to calculating
IU<sub>max</sub> based on Marinelli&#x02019;s formula by assuming that it
represented by the value of 24&#x02009;h thyroidal iodine uptake and can be predicted using
the <sup>123</sup>I uptake after 3&#x02009;h. They claim in their
publication that the algorithm they propose for determining the correlation between
the 3- and the 24-h thyroidal iodine uptake is statistically significant (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and can be used in clinical practice
[<xref ref-type="bibr" rid="CR8">8</xref>]. It has to be noted, however, that
as for practical application, this method has the distinct disadvantage of being
expensive, especially in Poland. The costs of producing the cyclotron-based iodine
isotope <sup>123</sup>I far outweighs those of acquiring the widely
used reactor-produced isotope of iodine, <sup>131</sup>I.</p><p id="Par27">Smith et al. present yet another strategy for assessing
IU<sub>max</sub> in the thyroid, although their research was conducted
on patients with non-toxic goitre, not with GD as in the case of the previously
mentioned authors. Departing from an analysis of the measurements of thyroid
<sup>99m</sup>Tc and <sup>131</sup>I uptake in
each of their 44 patients, Smith et al. created an algorithm estimating the 24-h
thyroid radioactive iodine uptake based on the level of
<sup>99m</sup>Tc uptake at 5&#x02009;min of administering the radiomarker.
They also emphasise that assessing iodine uptake on the basis of technetium
scintigraphy allows for the greatest reduction of the patients&#x02019; exposure to ionising
radiation. The thyroid absorbed dose of radiation emitted by technetium is 10 times
as low as it is when <sup>123</sup>I is used, and 10,000 lower than
in the case of treatment with <sup>131</sup>I. Also the effective
dose of ionising radiation received by the entire organism is markedly lower when
technetium is used for testing instead of <sup>123</sup>I or
<sup>131</sup>I iodine [<xref ref-type="bibr" rid="CR17">17</xref>]. The exposition from the diagnostic activity of radioiodine is
unimportant considering the dose received from the following radioiodine therapy.
Our study uses similar assumption as regards the prediction of thyroidal iodine
uptake on the basis of technetium uptake, the only difference being that our sample
consisted of patients with GD. The choice of study sample was determined by the fact
that in GD the thyroid tissue is usually homogeneous and there are no problems
associated with the occurrence of nodules that take up
<sup>99m</sup>Tc and <sup>131</sup>I in different
ways, as it is sometimes the case in a nodular goitre. These discrepancies result
from the lack of <sup>99m</sup>Tc organification by thyrocytes,
which occurs when <sup>131</sup>I is used [<xref ref-type="bibr" rid="CR18">18</xref>]. Had we additionally taken into consideration
the measurements of uptake values for the nodular goitre, the study sample would
have become overly heterogeneous, making the calculations imprecise.</p><p id="Par28">According to our investigations, the algorithm that depicts the
correlation between the uptakes of <sup>131</sup>I and
<sup>99m</sup>Tc is determined by the level of TRAb antibodies.
The level of TRAb that significantly changes the algorithm equals 10&#x02009;IU/ml. In
clinical practice, this means that when thyroidal iodine uptake is estimated in GD
patients on the basis of <sup>99m</sup>Tc uptake, the level of TRAb
antibodies should be taken into account so as to apply the correct algorithm.</p><p id="Par29">In conclusion, predicting the thyroidal uptake of
<sup>131</sup>IU<sub>24h</sub> in GD on the basis of
measuring <sup>99m</sup>TcU<sub>20min</sub> uptake is
possible, thanks to the equation created in the course of our research. The
application of this algorithm considerably shortens the time necessary for
pre-therapy diagnostic procedures and makes it possible to calculate the therapeutic
activity of radioactive iodine with the use of Marinelli&#x02019;s formula, as recommended
by the EANM.</p></sec></body><back><fn-group><fn><p>Ethical approval: All procedures performed in studies involving human
participants were in accordance with the ethical standards of the institutional
and/or national research committee and with the 1964 Helsinki declaration and its
later amendments or comparable ethical standards.</p></fn></fn-group><ack><p>We are grateful to all of the staff for helping with the data collection
and for the technical assistance. This paper was financed from statutory activity
funds of the Medical University of Bia&#x00142;ystok.</p></ack><notes notes-type="COI-statement"><title>Compliance with ethical standards</title><sec id="FPar1"><title>Conflict of interest</title><p id="Par30"> The authors declare that they have no conflict of interest.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stokkel</surname><given-names>MP</given-names></name><name><surname>Handkiewicz Junak</surname><given-names>D</given-names></name><name><surname>Lassmann</surname><given-names>M</given-names></name><name><surname>Dietlein</surname><given-names>M</given-names></name><name><surname>Luster</surname><given-names>M</given-names></name></person-group><article-title>EANM procedure guidelines for therapy of benign
thyroid disease</article-title><source>Eur. J. Nucl. Med. Mol. Imaging</source><year>2010</year><volume>37</volume><fpage>2218</fpage><lpage>2228</lpage><pub-id pub-id-type="doi">10.1007/s00259-010-1536-8</pub-id><pub-id pub-id-type="pmid">20625722</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vemulakonda</surname><given-names>US</given-names></name><name><surname>Atkins</surname><given-names>FB</given-names></name><name><surname>Ziessman</surname><given-names>HA</given-names></name></person-group><article-title>Therapy dose calculation in Graves&#x02019; disease using
early I-123 uptake measurements</article-title><source>Clin. Nucl. Med.</source><year>1996</year><volume>21</volume><fpage>102</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1097/00003072-199602000-00004</pub-id><pub-id pub-id-type="pmid">8697676</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hennessey</surname><given-names>JV</given-names></name><name><surname>Berg</surname><given-names>LA</given-names></name><name><surname>Ibrahim</surname><given-names>MA</given-names></name><name><surname>Markert</surname><given-names>RJ</given-names></name></person-group><article-title>Evaluation of early (5 to 6 hours) iodine 123 uptake
for diagnosis and treatment planning in Graves&#x02019; disease</article-title><source>Arch. Intern. Med.</source><year>1995</year><volume>155</volume><fpage>621</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1001/archinte.1995.00430060083010</pub-id><pub-id pub-id-type="pmid">7887758</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giovanella</surname><given-names>L</given-names></name><name><surname>Ceriani</surname><given-names>L</given-names></name><name><surname>Ghelfo</surname><given-names>A</given-names></name></person-group><article-title>Second-generation thyrotropin receptor antibodies
assay and quantitative thyroid scintigraphy in autoimmune
hyperthyroidism</article-title><source>Horm. Metab. Res.</source><year>2008</year><volume>40</volume><fpage>484</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1055/s-2008-1065320</pub-id><pub-id pub-id-type="pmid">18393171</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tepmongkol</surname><given-names>S</given-names></name></person-group><article-title>Enhancement of radioiodine uptake in hyperthyroidism
with hydrochlorothiazide: a prospective randomised control study</article-title><source>Eur. J. Nucl. Med. Mol. Imaging</source><year>2002</year><volume>29</volume><fpage>1307</fpage><lpage>1310</lpage><pub-id pub-id-type="doi">10.1007/s00259-002-0893-3</pub-id><pub-id pub-id-type="pmid">12271411</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marinelli</surname><given-names>LD</given-names></name><name><surname>Quimby</surname><given-names>EH</given-names></name><name><surname>Hine</surname><given-names>GJ</given-names></name></person-group><article-title>Dosage determination with radioactive isotopes;
practical considerations in therapy and protection</article-title><source>Am. J. Roentgenol. Radium Ther.</source><year>1948</year><volume>59</volume><fpage>260</fpage><lpage>281</lpage></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobe</surname><given-names>C</given-names></name><name><surname>Eschner</surname><given-names>W</given-names></name><name><surname>Wild</surname><given-names>M</given-names></name><name><surname>Rahlff</surname><given-names>I</given-names></name><name><surname>Sudbrock</surname><given-names>F</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Dietlein</surname><given-names>M</given-names></name><name><surname>Schicha</surname><given-names>H</given-names></name></person-group><article-title>Radioiodine therapy of benign thyroid disorders: what
are the effective thyroidal half-life and uptake of 131I?</article-title><source>Nucl. Med. Commun.</source><year>2010</year><volume>31</volume><fpage>201</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1097/MNM.0b013e328333d303</pub-id><pub-id pub-id-type="pmid">19907353</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osaki</surname><given-names>Y</given-names></name><name><surname>Sakurai</surname><given-names>K</given-names></name><name><surname>Arihara</surname><given-names>Z</given-names></name><name><surname>Hata</surname><given-names>M</given-names></name><name><surname>Fukazawa</surname><given-names>H</given-names></name></person-group><article-title>Prediction of late (24-hour) radioactive iodine uptake
using early (3-hour) uptake values in Japanese patients with Graves&#x02019;
disease</article-title><source>Endocr. J.</source><year>2012</year><volume>59</volume><fpage>173</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1507/endocrj.EJ11-0279</pub-id><pub-id pub-id-type="pmid">22095001</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hautzel</surname><given-names>H</given-names></name><name><surname>Pisar</surname><given-names>E</given-names></name><name><surname>Yazdan-Doust</surname><given-names>N</given-names></name><name><surname>Schott</surname><given-names>M</given-names></name><name><surname>Beu</surname><given-names>M</given-names></name><name><surname>M&#x00171;ller</surname><given-names>HW</given-names></name></person-group><article-title>Qualitative and quantitative impact of protective
glucocorticoid therapy on the effective 131I half-life in radioiodine therapy
for Graves&#x02019; disease</article-title><source>J. Nucl. Med.</source><year>2010</year><volume>51</volume><fpage>1917</fpage><lpage>1922</lpage><pub-id pub-id-type="doi">10.2967/jnumed.110.080473</pub-id><pub-id pub-id-type="pmid">21078788</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Traino</surname><given-names>AC</given-names></name><name><surname>Di Martino</surname><given-names>F</given-names></name><name><surname>Lazzeri</surname><given-names>M</given-names></name><name><surname>Stabin</surname><given-names>MG</given-names></name></person-group><article-title>Study of the correlation between administered activity
and radiation committed dose to the thyroid in 131I therapy of Graves&#x02019;
disease</article-title><source>Radiat. Prot. Dosimetry</source><year>2001</year><volume>95</volume><fpage>117</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.rpd.a006531</pub-id><pub-id pub-id-type="pmid">11572639</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Read</surname><given-names>CH</given-names></name><name><surname>Tansey</surname><given-names>MJ</given-names></name><name><surname>Menda</surname><given-names>Y</given-names></name></person-group><article-title>A 36-year retrospective analysis of the efficacy and
safety of radioactive iodine in treating young Graves&#x02019; patients</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2004</year><volume>89</volume><fpage>4229</fpage><lpage>4233</lpage><pub-id pub-id-type="doi">10.1210/jc.2003-031223</pub-id><pub-id pub-id-type="pmid">15356012</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiavo</surname><given-names>M</given-names></name><name><surname>Bagnara</surname><given-names>MC</given-names></name><name><surname>Camerieri</surname><given-names>L</given-names></name><name><surname>Pomposeli</surname><given-names>E</given-names></name><name><surname>Giusti</surname><given-names>M</given-names></name><name><surname>Pesce</surname><given-names>G</given-names></name><name><surname>Reitano</surname><given-names>C</given-names></name><name><surname>Caputo</surname><given-names>M</given-names></name><name><surname>Bagnasco</surname><given-names>M</given-names></name></person-group><article-title>Clinical efficacy of radioiodine therapy in
multinodular toxic goiter, applying an implemented dose calculation
algorithm</article-title><source>Endocrine</source><year>2015</year><volume>48</volume><fpage>902</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1007/s12020-014-0398-4</pub-id><pub-id pub-id-type="pmid">25151403</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>LF</given-names></name><name><surname>Waxman</surname><given-names>AD</given-names></name><name><surname>Braunstein</surname><given-names>GD</given-names></name></person-group><article-title>Accuracy considerations when using early (four- or
six-hour) radioactive iodine uptake to predict twenty-four-hour values for
radioactive iodine dosage in the treatment of Graves&#x02019; disease</article-title><source>Thyroid</source><year>2000</year><volume>10</volume><fpage>779</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1089/thy.2000.10.779</pub-id><pub-id pub-id-type="pmid">11041455</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>AA</given-names></name><name><surname>Akre</surname><given-names>CM</given-names></name><name><surname>Gorman</surname><given-names>CA</given-names></name></person-group><article-title>Iodine-131 treatment of Graves&#x02019; disease using modified
early iodine-131 uptake measurements in therapy dose calculations</article-title><source>J. Nucl. Med.</source><year>1990</year><volume>31</volume><fpage>519</fpage><lpage>522</lpage><pub-id pub-id-type="pmid">2324829</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yaqub</surname><given-names>A</given-names></name><name><surname>Choudhry</surname><given-names>MI</given-names></name><name><surname>Wheaton</surname><given-names>J</given-names></name><name><surname>Gress</surname><given-names>T</given-names></name></person-group><article-title>Post-ablative hypothyroidism</article-title><source>W. V. Med. J.</source><year>2011</year><volume>107</volume><fpage>37</fpage><lpage>40</lpage></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>B</given-names></name><name><surname>Zanin</surname><given-names>DE</given-names></name><name><surname>Schipper</surname><given-names>R</given-names></name></person-group><article-title>Reference-free thyroid uptake
measurement</article-title><source>Nucl. Med. Commun.</source><year>2014</year><volume>35</volume><fpage>382</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1097/MNM.0000000000000071</pub-id><pub-id pub-id-type="pmid">24569705</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>JJ</given-names></name><name><surname>Croft</surname><given-names>BY</given-names></name><name><surname>Brookeman</surname><given-names>VA</given-names></name><name><surname>Teates</surname><given-names>CD</given-names></name></person-group><article-title>Estimation of 24-hour thyroid uptake of I-131 sodium
iodide using a 5-minute uptake of technetium-99m pertechnetate</article-title><source>Clin. Nucl. Med.</source><year>1990</year><volume>15</volume><fpage>80</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1097/00003072-199002000-00003</pub-id><pub-id pub-id-type="pmid">2155732</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kusi&#x00107;</surname><given-names>Z</given-names></name><name><surname>Becker</surname><given-names>DV</given-names></name><name><surname>Saenger</surname><given-names>EL</given-names></name><name><surname>Paras</surname><given-names>P</given-names></name><name><surname>Gartside</surname><given-names>P</given-names></name><name><surname>Wessler</surname><given-names>T</given-names></name><name><surname>Spaventi</surname><given-names>S</given-names></name></person-group><article-title>Comparison of technetium-99m and iodine-123 imaging of
thyroid nodules: correlation with pathologic findings</article-title><source>J. Nucl. Med.</source><year>1990</year><volume>31</volume><fpage>393</fpage><lpage>399</lpage><pub-id pub-id-type="pmid">2157829</pub-id></element-citation></ref></ref-list></back></article>